Cargando…

Costs of Illness of Spinal Muscular Atrophy: A Systematic Review

OBJECTIVES: The objective of our study was to conduct a systematic literature review of estimates of costs of illness of spinal muscular atrophy (SMA). METHODS: We searched MEDLINE (through PubMed), CINAHL, Embase, Web of Science, National Health Service Economic Evaluation Database, and the Nationa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Landfeldt, Erik, Pechmann, Astrid, McMillan, Hugh J., Lochmüller, Hanns, Sejersen, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270802/ https://www.ncbi.nlm.nih.gov/pubmed/33576939 http://dx.doi.org/10.1007/s40258-020-00624-2

Ejemplares similares

Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis
por: Landfeldt, Erik, et al.
Publicado: (2020)

Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2019)

Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
por: Landfeldt, Erik, et al.
Publicado: (2016)

SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy
por: Pechmann, Astrid, et al.
Publicado: (2019)

Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management
por: Paracha, Noman, et al.
Publicado: (2021)

Health-Related Quality of Life in Patients with Adult-Onset Myotonic Dystrophy Type 1: A Systematic Review
por: Landfeldt, Erik, et al.
Publicado: (2019)

Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada
por: McMillan, H.J., et al.
Publicado: (2021)

Quantifying the burden of caregiving in Duchenne muscular dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2016)

Advances in Treatment of Spinal Muscular Atrophy – New Phenotypes, New Challenges, New Implications for Care
por: Schorling, David C., et al.
Publicado: (2020)

Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)
por: Paracha, Noman, et al.
Publicado: (2021)

Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic Review
por: Aragon-Gawinska, Karolina, et al.
Publicado: (2023)

Compliance to Care Guidelines for Duchenne Muscular Dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2015)

Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers
por: Sutherland, C. Simone, et al.
Publicado: (2021)

The burden of Duchenne muscular dystrophy: An international, cross-sectional study
por: Landfeldt, Erik, et al.
Publicado: (2014)

Health‐related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross‐sectional study
por: Landfeldt, Erik, et al.
Publicado: (2015)

Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study
por: Kiefer, Petra, et al.
Publicado: (2020)

Extending Life in Duchenne Muscular Dystrophy: Implications for Appraisals of Cost-Effectiveness
por: Landfeldt, Erik
Publicado: (2018)

Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy
por: Kichula, Elizabeth A., et al.
Publicado: (2021)

Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence
por: Hjartarson, Helgi Thor, et al.
Publicado: (2022)

The Safety and Efficacy of Nusinersen in the Treatment of Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Abbas, Kirellos Said, et al.
Publicado: (2022)

Safety and Efficacy of Nusinersen and Risdiplam for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Qiao, Yue, et al.
Publicado: (2023)

A National Spinal Muscular Atrophy Registry for Real-World Evidence
por: Hodgkinson, Victoria L., et al.
Publicado: (2020)

Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review
por: Verhaart, Ingrid E. C., et al.
Publicado: (2017)

Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment
por: Nigro, Elisa, et al.
Publicado: (2023)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Evaluating case management for caregivers of children with spinal muscular atrophy type I and II—an exploratory, controlled, mixed-methods trial
por: Willems, Jana, et al.
Publicado: (2023)

Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients
por: Lochmüller, Hanns, et al.
Publicado: (2018)

Gene therapy for spinal muscular atrophy: the benefit–cost profile
Publicado: (2021)

Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England
por: Weidlich, Diana, et al.
Publicado: (2023)

Multispectral optoacoustic tomography for non-invasive disease phenotyping in pediatric spinal muscular atrophy patients
por: Regensburger, Adrian P., et al.
Publicado: (2021)

Abnormal fatty acid metabolism is a core component of spinal muscular atrophy
por: Deguise, Marc‐Olivier, et al.
Publicado: (2019)

Carrier screening for spinal muscular atrophy
por: Prior, Thomas W.
Publicado: (2008)

European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
por: Kirschner, Janbernd, et al.
Publicado: (2020)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Spinal Muscular Atrophy and Ependymoma
por: Albakr, Aishah, et al.
Publicado: (2017)

Risdiplam for spinal muscular atrophy
Publicado: (2022)

“Suddenly we have hope that there is a future”: two families’ narratives when a child with spinal muscular atrophy receives a new drug
por: Hjorth, Elin, et al.
Publicado: (2021)

High-sensitive cardiac troponin I (hs-cTnI) concentrations in newborns diagnosed with spinal muscular atrophy
por: Johannsen, Jessika, et al.
Publicado: (2023)

Survival Motor Neuron Protein is Released from Cells in Exosomes: A Potential Biomarker for Spinal Muscular Atrophy
por: Nash, Leslie A., et al.
Publicado: (2017)

Splice-Switching Therapy for Spinal Muscular Atrophy
por: Meijboom, Katharina E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gl614ar5is8buvph5jaeua2bnr